- Hepatic Immunoglobulin G4-related Inflammatory Pseudotumor Mimicking Hepatocellular Carcinoma
-
Seung Heon Kang, Sang Hoon Park, Ho Hyun Park, Jeong Rok Lee, Won Hyeok Choe, So Dug Lim, Soon Young Ko
-
J Liver Cancer. 2016;16(2):151-154. Published online September 30, 2016
-
DOI: https://doi.org/10.17998/jlc.16.2.151
-
-
Abstract
PDF
- Immunoglobulin G4-related disease is a recently recognized entity characterized by a massforming
or regional lesion that contains an extensive infiltration of IgG4-producing plasma
cells with dense fibrosis. Immunoglobulin G4-related disease can affect any organ system,
but solitary hepatic lesion of Immunoglobulin G4-related disease is very rare. This entity
mimics primary malignant hepatic tumor, such as hepatocellular carcinoma or intrahepatic
cholangiocarcinoma. We experienced a case of hepatic IgG4-related inflammatory
pseudotumor in a 50-year-old woman, mimicking hepatocellular carcinoma.
- Survival Benefit of Antiviral Agents for Hepatocellular Carcinoma Patients Treated with Sorafenib
-
Jeong Han Kim, Hyung Min Yu, Yong Hwang, Soon Young Ko, Won Hyeok Choe, So Young Kwon
-
J Liver Cancer. 2016;16(1):23-30. Published online March 31, 2016
-
DOI: https://doi.org/10.17998/jlc.16.1.23
-
-
Abstract
PDF
- Background/Aim
s: Nucleos(t)ide analogues (NAs) help reduce the recurrence rate after
the curative treatment of hepatitis B related hepatocellular carcinoma (HCC). Sorafenib has
been shown to improve survival of advanced HCC patients. Whether antiviral therapy with
NAs could help such patients is unknown. Our aim is to investigate the usefulness of antiviral
therapy for advanced-stage HCC treated with sorafenib.
Methods We performed a retrospective cohort study in advanced-stage HCC patients
treated with sorafenib between June 2007 and December 2013. Patients in group A (the nonantiviral
therapy group) were treated with sorafenib alone. Those in group B (the antiviral
therapy group) were treated with sorafenib and NAs. Progression-free survival (PS) and overall
survival (OS) were compared between these two groups.
Results Finally, 23 patients in group A and 40 patients in group B were enrolled in the study.
The mean number of days of treatment with sorafenib was 79 (34-231) days and 96 (33-449)
days for group A and B, respectively (P=0.286). The mean PS of group A and B was 97 (14-449)
days and 51 (0-461) days, respectively (P=0.068). The OS was 154 (44-741) days in group A and
138 (30-1,025) days in group B (P=0.665). PS and OS showed no significant difference between
the two groups.
Conclusions This study shows that there was no significant survival gain of using antiviral
therapy in patients with advanced-stage HCC treated with sorafenib. In consideration of costeffectiveness,
antiviral therapy may be not mandatory. (J Liver Cancer 2016;16:23-30)
|